admin
Brian Lian’s story reads like the kind of American success the left pretends to admire but rarely understands: a Wall Street analyst who walked away from a comfortable career to build a biotech company that now commands multi‑billion dollar attention. Viking Therapeutics is sitting squarely in the middle of the GLP‑1 gold rush, and that rise from a tiny startup to a roughly $4 billion market capitalization is proof that free enterprise still produces winners when left alone to compete.
Lian didn’t inherit a monopoly or a bailout — he struck a deal, convinced Ligand Pharmaceuticals to license compounds and kick in seed funding, and set to work building a pipeline focused on metabolic disease. That kind of grit and deal-making is the backbone of American innovation, not the result of government fiat or big pharma cronyism. The origin story underscores how private-sector risk-taking, not regulatory handouts, fuels breakthroughs.
Viking’s lead program, VK2735, has produced eye‑opening Phase 2 results and is now being evaluated in large Phase 3 VANQUISH trials, while the company pushes both injectable and oral formulations — a strategic play that could let patients switch regimens without losing progress. Viking’s own filings and press announcements show up to 14.7 percent mean weight loss in trial participants and rapid enrollment in VANQUISH-1 and VANQUISH-2, evidence that investors and patients alike see real clinical potential. Those are the facts that make Viking an attractive target whether it wants to be bought or not.
Big pharmaceutical players are circling, and the money on the table is staggering — analysts and reporting now peg the obesity and metabolic drug space as a potential hundred‑billion dollar opportunity or more as companies expand indications and access. That’s why giants are either buying talent and technology or racing to develop their own next‑gen therapies; this is not altruism, it’s competition for market share in a booming sector. Americans should celebrate the innovation, but remain wary of the concentration that follows such gold rushes.
Let’s be blunt: when billion‑dollar prizes are within reach, praise and press turn into price tags and bargaining chips. The current GLP‑1 craze — led by household names like Novo Nordisk and Eli Lilly — has been hyped as a miracle by the media, but it’s ultimately a commercial battleground where consumers can pay the price for convenience and marketing. We should cheer advances that help people live healthier lives while demanding transparency on outcomes, side effects, and long‑term costs from both the companies and the regulators who rubber‑stamp approvals.
That’s why vigilance matters: the same forces that drive innovation can also drive consolidation, and recent deals show the appetite among large drugmakers to buy their way into new markets rather than build from scratch. When Pfizer and others spend billions to snap up promising assets, consumers and taxpayers deserve scrutiny of how these deals affect drug prices, access, and the independence of clinical development. This is not a case for anti‑innovation hostility, it’s a call to ensure competition and accountability remain front and center.
At bottom, Brian Lian’s Viking is a reminder that American entrepreneurs still create value and shake up entrenched interests, and conservatives should be the loudest champions of that truth. We should back policies that keep markets open, protect competition, and prevent regulatory capture so more scrappy startups can challenge the giants. If we preserve those principles, hardworking Americans will keep reaping the rewards of private enterprise rather than watching healthcare become another arena for concentrated corporate power.
